LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
← catalyst calendarNCT07415044 · readout ≤ 1,411 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Double · Treatment
Enrollment
1,431estimated
Sites
258
Countries
Argentina, Brazil, Canada +25
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-26 | actual | When the study began enrolling |
| Primary completion | Jun 2030 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jul 2031 | estimated | The whole study's end, after follow-up |
| First posted | 2026-02-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-06 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Ulcerative Colitis (UC)
- Ulcerative Colitis, Active Moderate
- Ulcerative Colitis, Active Severe
Interventions
- Drug: LY4268989 — also filed as MORF-057, zotemtegrast
- Drug: Placebo
Primary outcomes
what the primary-completion date above is the date OFPercentage of Participants Who Achieve Clinical Remission with Modified Mayo Score (mMS)
measured Week 10
Percentage of Participants Who Achieve Clinical Remission with mMS Among Participants Who Achieved Clinical Response with LY4268989 at Week 10
measured Week 52
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed